Suppr超能文献

澳大利亚参考人群中肌钙蛋白检测第99百分位数水平的测定。

The determination of the 99th centile level for troponin assays in an Australian reference population.

作者信息

Tate Jillian R, Ferguson Wendy, Bais Renze, Kostner Karam, Marwick Thomas, Carter Andrew

机构信息

Chemical Pathology Department, Pathology Queensland, Royal Brisbane and Women's Hospital, Herston, QLD 4029, Australia.

出版信息

Ann Clin Biochem. 2008 May;45(Pt 3):275-88. doi: 10.1258/acb.2007.007185.

Abstract

BACKGROUND

Current guidelines for the diagnosis and risk assessment of patients presenting with myocardial infarction recommend a single decision cut-off point for cardiac troponin (cTn) based on the 99th centile of a reference population. The 99th centile level for eight troponin assays was determined in an apparently cardio-healthy Australian reference population.

METHODS

Nine laboratories measured troponin in serum and plasma collected from 111 reference individuals. An imprecision profile was determined using up to 10 serum samples analysed on 10 separate days. Method comparison using 100 routinely tested plasma samples was performed to estimate method concordance.

RESULTS

Generally 99th centile values determined in this study were lower than, or the same as manufacturers' levels, except for cTnI by Architect (0.020 vs. 0.012 microg/L), and imprecision at the 99th centile was 20% coefficient of variation (CV) or higher. Troponin concentrations at 10% CV were greater than those quoted in the manufacturer's package insert except by AxSYM, 0.06 vs. 0.16 microg/L cTnI, and by E-170, 0.02 vs. 0.03 microg/L cTnT. In the method comparison 74, 70, 65, 75, 58, 66, 58 and 77 samples measured by Access, Architect, AxSYM, Centaur, Dimension RxL, E-170, i-STAT and Vitros ECi assays, respectively, had troponin concentrations above the study 99th centile.

CONCLUSIONS

Depending on the selected reference population for troponin, there is likely to be variability in the 99th centile as shown in this study. Some differences in sample concordance at the 99th centile cut-off were observed between cTn methods and may result in different clinical classification.

摘要

背景

目前关于心肌梗死患者诊断和风险评估的指南推荐基于参考人群第99百分位数确定心肌肌钙蛋白(cTn)的单一判定临界点。在表面上心脏健康的澳大利亚参考人群中确定了8种肌钙蛋白检测方法的第99百分位数水平。

方法

9个实验室检测了从111名参考个体采集的血清和血浆中的肌钙蛋白。使用在10个不同日期分析的多达10份血清样本确定不精密度概况。使用100份常规检测的血浆样本进行方法比较以估计方法一致性。

结果

一般来说,本研究中确定的第99百分位数低于或等于制造商给出的水平,但Architect检测的cTnI除外(0.020对0.012μg/L),第99百分位数处的不精密度为变异系数(CV)20%或更高。CV为10%时的肌钙蛋白浓度高于制造商包装说明书中引用的浓度,但AxSYM检测的cTnI除外(0.06对0.16μg/L)以及E-170检测的cTnT除外(0.02对0.03μg/L)。在方法比较中,Access、Architect、AxSYM、Centaur、Dimension RxL、E-170、i-STAT和Vitros ECi检测法分别检测的74、70、65、75、58、66、58和77份样本的肌钙蛋白浓度高于研究的第99百分位数。

结论

正如本研究所示,根据所选的肌钙蛋白参考人群,第99百分位数可能存在变异性。在第99百分位数临界点处,cTn检测方法之间在样本一致性方面存在一些差异,这可能导致不同的临床分类。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验